MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Thursday reported a loss of $6.9 million in its second quarter.

The Mountain View, California-based company said it had a loss of 14 cents per share.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share.

The biopharmaceutical company posted revenue of $15 million in the period, which also missed Street forecasts. Three analysts surveyed by Zacks expected $16.9 million.

ChemoCentryx shares have increased 95 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $11.60, a climb of 48 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI